140 related articles for article (PubMed ID: 35172482)
1. Acral Lentiginous Melanoma Harboring a
Couts KL; McCoach CE; Murphy D; Christiansen J; Turner J; Lewis KD; Robinson WA; Doebele RC
JCO Precis Oncol; 2017 Nov; 1():1-7. PubMed ID: 35172482
[TBL] [Abstract][Full Text] [Related]
2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
3. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
[TBL] [Abstract][Full Text] [Related]
4. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
5. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
[TBL] [Abstract][Full Text] [Related]
6. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
7. ALK Inhibitor Response in Melanomas Expressing
Couts KL; Bemis J; Turner JA; Bagby SM; Murphy D; Christiansen J; Hintzsche JD; Le A; Pitts TM; Wells K; Applegate A; Amato C; Multani P; Chow-Maneval E; Tentler JJ; Shellman YG; Rioth MJ; Tan AC; Gonzalez R; Medina T; Doebele RC; Robinson WA
Mol Cancer Ther; 2018 Jan; 17(1):222-231. PubMed ID: 29054983
[TBL] [Abstract][Full Text] [Related]
8. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date.
Araujo JM; Gomez AC; Pinto JA; Rolfo C; Raez LE
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):192-198. PubMed ID: 33290717
[TBL] [Abstract][Full Text] [Related]
9. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A
Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an
Farago AF; Taylor MS; Doebele RC; Zhu VW; Kummar S; Spira AI; Boyle TA; Haura EB; Arcila ME; Benayed R; Aisner DL; Horick NK; Lennerz JK; Le LP; Iafrate AJ; Ou SI; Shaw AT; Mino-Kenudson M; Drilon A
JCO Precis Oncol; 2018; 2018():. PubMed ID: 30215037
[TBL] [Abstract][Full Text] [Related]
11. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
12. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
[TBL] [Abstract][Full Text] [Related]
13. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
14. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS
Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of
Liu D; Offin M; Harnicar S; Li BT; Drilon A
Ther Clin Risk Manag; 2018; 14():1247-1252. PubMed ID: 30050303
[TBL] [Abstract][Full Text] [Related]
17. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno T; Nakaoku T; Tsuta K; Tsuchihara K; Matsumoto S; Yoh K; Goto K
Transl Lung Cancer Res; 2015 Apr; 4(2):156-64. PubMed ID: 25870798
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Efficacy and Safety of Entrectinib in
Drilon A; Chiu CH; Fan Y; Cho BC; Lu S; Ahn MJ; Krebs MG; Liu SV; John T; Otterson GA; Tan DSW; Patil T; Dziadziuszko R; Massarelli E; Seto T; Doebele RC; Pitcher B; Kurtsikidze N; Heinzmann S; Siena S
JTO Clin Res Rep; 2022 Jun; 3(6):100332. PubMed ID: 35663414
[TBL] [Abstract][Full Text] [Related]
19. Primary and Metastatic Melanoma With NTRK Fusions.
Lezcano C; Shoushtari AN; Ariyan C; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Aug; 42(8):1052-1058. PubMed ID: 29683819
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]